Investors Urge Teva To Split Up After CEO’s Abrupt Departure
Teva Pharmaceuticals(TEVA), the world’s largest producer of generic drugs, is in turmoil. Last week, the company lost a key patent ruling regarding its blockbuster drug, Copaxone. Copaxone, which can maintain remission for multiple sclerosis patients, accounts for one-fifth of Teva’s revenue. The introduction of generic competition, which now seems likely, will result in a major drop in revenue… Read More »